1. High-efficiency transformation of influenza virus transfectants;Enami;J. Virol.,1991
2. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine;Subbarao;J. Virol.,1995
3. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses;Li;J. Infect. Dis.,1999
4. Treanor J, Betts R, Powers D, Belshe R, Anderson E, Lakey D, et al. Evaluation of recombinant influenza virus haemagglutining (Has) expressed in insect cells as influenza vaccines in humans. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza III. Amsterdam: Elsevier, 1996. p. 677–82.
5. Katz J, Treanor J. Vaccines and related biological products advisory committee. Center for Biologicals Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA, 29 January 1999.